|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 09-01 | Canaccord Genuity Initiates Aclaris Therapeutics at Buy With $10 Price Target | MT |
| 08-06 | Aclaris Therapeutics Gets Fast-Track Designation for Inflammation Treatment Modzatinib | DJ |
| Market Cap | 774M 689M 643M 587M 1.1B 74.57B 1.12B 7.76B 3.01B 38B 2.91B 2.84B 122B | P/E 2026 * |
-8.14x | P/E 2027 * | -6.69x |
|---|---|---|---|---|---|
| Enterprise Value | 621M 553M 516M 471M 883M 59.82B 896M 6.23B 2.42B 30.48B 2.33B 2.28B 98.17B | EV / Sales 2026 * |
98x | EV / Sales 2027 * | 118x |
| Free-Float |
97.82% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ACLS THER
| Manager | Title | Age | Since |
|---|---|---|---|
Neal Walker
CEO | Chief Executive Officer | 56 | 2024-01-16 |
Hugh Davis
PSD | President | 67 | 2024-11-17 |
Kevin Balthaser
DFI | Director of Finance/CFO | 39 | 2022-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Neal Walker
CHM | Chairman | 56 | 2022-12-31 |
Anand Mehra
BRD | Director/Board Member | 50 | 2014-08-31 |
| Director/Board Member | 59 | 2016-08-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.16% | -0.36% | +49.37% | +94.17% | 74.46B | |
| -0.61% | +0.69% | +36.36% | +82.72% | 60.14B | |
| -2.54% | -0.21% | +6.34% | +31.72% | 48.15B | |
| -3.02% | -2.67% | +37.26% | +32.51% | 44.25B | |
| +0.31% | +7.94% | +340.88% | +643.82% | 43.99B | |
| -1.96% | -1.71% | +5.30% | +99.46% | 41.61B | |
| +3.32% | +3.49% | +11.18% | +51.23% | 29.97B | |
| +4.77% | +6.16% | +36.77% | +22.78% | 29.31B | |
| -4.86% | -8.24% | -24.60% | +330.06% | 24.93B | |
| Average | -0.05% | +1.97% | +55.43% | +154.28% | 44.09B | |
| Weighted average by Cap. | +0.17% | +1.83% | +60.06% | +145.78% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 6.34M 5.64M 5.26M 4.81M 9.01M 610M 9.15M 63.55M 24.65M 311M 23.8M 23.28M 1B | 5.34M 4.75M 4.43M 4.05M 7.59M 514M 7.7M 53.52M 20.76M 262M 20.04M 19.61M 844M |
| Net income | -90.33M -80.39M -75.01M -68.49M -128M -8.7B -130M -906M -351M -4.43B -339M -332M -14.28B | -112M -99.98M -93.29M -85.17M -160M -10.82B -162M -1.13B -437M -5.51B -422M -413M -17.75B |
| Net Debt | -153M -136M -127M -116M -218M -14.75B -221M -1.53B -595M -7.51B -575M -562M -24.2B | -147M -130M -122M -111M -208M -14.11B -212M -1.47B -570M -7.19B -550M -538M -23.16B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
